At 6.9% CAGR, Asia Pacific Parenteral Nutrition Market is Projected to be Worth US$ 1,471.33 Million by 2030, says Business Market Insights

According to Business Market Insights' research, the Asia Pacific parenteral nutrition market was valued at US$ 861.59 million in 2022 and is expected to reach US$ 1,471.33 million by 2030, registering a CAGR of 6.9% from 2022 to 2030. Surge in cases of malnutrition and premature births and innovation in formulations of nutrition products are among the critical factors attributed to the Asia Pacific parenteral nutrition market expansion.

Malnutrition includes being undernourished, overweight or obese, having inadequate vitamins or minerals, and having a non-communicable disease due to a bad diet. As per World Health Organization (WHO) data, ~1.9 billion adults were overweight or obese, whereas 462 million were underweight in 2021. Additionally, 39 million children under the age of 5 were overweight, 149 million had stunted growth and development as a result of a chronic lack of nutrient-rich food in their diets, and 45 million were wasted (too thin for height). Furthermore, ~45% of deaths among children aged less than 5 are associated with undernutrition. As per the July 2022 data of the United Nations International Children's Emergency Fund (UNICEF), the prevalence of undernourishment reached 9.3% in 2020 from 8.0% in 2019; it further jumped to 9.8% in 2021.

Nutritional support delivered through parenteral methods, depending on the need, is an important and appropriate way of treating most malnutrition cases.

Preterm birth refers to a baby being born at a significantly early stage, i.e., before the completion of 37 weeks of pregnancy. As per the WHO data published in 2023, ~13.4 million preterm births (more than 1 in 10 births) were reported worldwide in 2020. Additionally, most preterm births (more than 60%) occurred in southern Asia and sub-Saharan Africa in 2021, which is becoming a global concern. On average, 12% of babies in low-income countries are born too early, compared to 9% in high-income countries. A large number of premature babies suffer from low weight and undeveloped immunity, which puts their lives at risk. Parenteral nutrition is preferred in preterm infants due to sucking or swallowing difficulties as a complication of an immature birth or due to neuromuscular, heart, or other disorders. When estimated energy and nutritional requirements cannot be safely met by enteral route right after birth, parenteral nutrition (PN) is part of the routine nutrition care for premature neonates and infants.

Thus, the huge burden of malnutrition in children and adults and the high number of preterm births drive the demand for parenteral nutrition formulae and products, which drives the market.

On the contrary, mechanical, gastrointestinal, and metabolic complications associated with parenteral feeding systems hampers the growth of Asia Pacific parenteral nutrition market.

Based on nutrient type, the Asia Pacific parenteral nutrition market is categorized into single dose amino acid solution, parenteral lipid emulsion, carbohydrates, trace elements, and vitamins and minerals. The single dose amino acid solution segment held 33.2% market share in 2022, amassing US$ 285.70 million. It is projected to garner US$ 484.20 million by 2030 to register 6.8% CAGR during 2022-2030.

In terms of end user, the Asia Pacific parenteral nutrition market is segmented into hospitals, clinics, and others. The hospitals segment held 59.5% share of Asia Pacific parenteral nutrition market in 2022, amassing US$ 512.36 million. It is projected to garner US$ 856.52 million by 2030 to expand at 6.6% CAGR during 2022-2030.

Based on country, the Asia Pacific parenteral nutrition market has been categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Our regional analysis states that China captured 27.4% share of Asia Pacific parenteral nutrition market in 2022. It was assessed at US$ 235.94 million in 2022 and is likely to hit US$ 416.07 million by 2030, exhibiting a CAGR of 7.3% during 2022-2030.

Key players operating in the Asia Pacific parenteral nutrition market are ICU Medical Inc, Grifols SA, Pfizer Inc, Otsuka Pharmaceuticals Co Ltd, Baxter International Inc, B Braun SE, Fresenius Kabi AG, Aculife Healthcare Pvt Ltd, Sichuan Kelun-Biotech Biopharmaceutical Co Ltd, and Vifor Pharma Management AG, among others.

• In November 2020, Otsuka Pharmaceuticals Co Ltd launched "ENEFLUID Injection," the amino acid, glucose, electrolyte, fat, and water-soluble vitamin injection. This product is the first peripheral parenteral nutrition solution in Japan that combines fat and water-soluble vitamins in addition to glucose, electrolytes, and amino acids in a dual-chamber bag.
  
  

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com